In the review article are provided the approaches to the therapy for improvement of prognosis in patients with peripheral and multifocal atherosclerosis which are available now; some limitations and a real situation are designated for the antithrombotic therapy in this category of patients. According to the clinical trial COMPASS the prospects of wide use of a combination of acetylsalicylic acid and a rivaroxsaban of 2.5 mg 2 times a day in the patients with chronic coronary heart disease and/or symptom peripheral atherosclerosis are designated.
CITATION STYLE
Barbarash, O. L., & Kashtalap, V. V. (2019). Do the patients with peripheral atherosclerosis need to a medical therapy before the revascularization? Terapevticheskii Arkhiv, 91(12), 129–134. https://doi.org/10.26442/00403660.2019.12.000498
Mendeley helps you to discover research relevant for your work.